MCL1 and cancer: Activation of the PI3K/AKT pathway contributes to multidrug resistance (via ABCG2), alters the drug metabolism (via CYP3A4), and enhances cell survival (via MCL1), all of which play key roles in cancer cell resistance to chemotherapy drugs like irinotecan [[21], [22], [23]].